NEO
Price
$16.83Alerts
Change
-$0.13 (-0.77%)
Updated
Nov 11 closing price
Capitalization
2.16B
104 days until earnings call
Intraday BUY SELL Signals
XGN
Price
$5.04Alerts
Change
-$0.23 (-4.37%)
Updated
Nov 11 closing price
Capitalization
140.75M
125 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NEO vs XGN

NEO vs XGN Comparison Chart in %
View a ticker or compare two or three
VS
NEO vs. XGN commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NEO is a Hold and XGN is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NEO with price predictions
Nov 10, 2026

NEO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for NEO turned positive on October 27, 2026. Looking at past instances where NEO's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +6.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEO advanced for three days, in 216 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 55 cases where NEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NEO as a result. In 65 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

NEO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NEO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

NEO broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.754) is normal, around the industry mean (67.298). P/E Ratio (-43.179) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (9.775).

The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

A.I.Advisor
a Summary for XGN with price predictions
Nov 10, 2026

XGN's RSI Indicator ascends from oversold territory

The RSI Oscillator for XGN moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 33 of the 36 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 160 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XGN crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.522) is normal, around the industry mean (67.298). P/E Ratio (-7.085) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

FUNDAMENTALS RATINGS
NEO vs XGN: Fundamental Ratings
NEO
XGN
OUTLOOK RATING
1..100
2754
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9299
PRICE GROWTH RATING
1..100
3644
P/E GROWTH RATING
1..100
7076
SEASONALITY SCORE
1..100
3131

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NEO's Valuation (27) in the Medical Or Nursing Services industry is in the same range as XGN (40) in the null industry. This means that NEO’s stock grew similarly to XGN’s over the last 12 months.

NEO's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as XGN (100) in the null industry. This means that NEO’s stock grew similarly to XGN’s over the last 12 months.

NEO's SMR Rating (92) in the Medical Or Nursing Services industry is in the same range as XGN (99) in the null industry. This means that NEO’s stock grew similarly to XGN’s over the last 12 months.

NEO's Price Growth Rating (36) in the Medical Or Nursing Services industry is in the same range as XGN (44) in the null industry. This means that NEO’s stock grew similarly to XGN’s over the last 12 months.

NEO's P/E Growth Rating (70) in the Medical Or Nursing Services industry is in the same range as XGN (76) in the null industry. This means that NEO’s stock grew similarly to XGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NEOXGN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (NEO: $16.96 vs. XGN: $5.26)
Brand notoriety: NEO and XGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NEO: 86% vs. XGN: 601%
Market capitalization -- NEO: $2.16B vs. XGN: $140.75M
NEO [@Medical Specialties] is valued at $2.16B. XGN’s [@Medical Specialties] market capitalization is $140.75M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Medical Specialties] industry is $20.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NEO’s FA Score shows that 1 FA rating(s) are green while XGN’s FA Score has 0 green FA rating(s).

  • NEO’s FA Score: 1 green, 4 red.
  • XGN’s FA Score: 0 green, 5 red.
According to our system of comparison, both NEO and XGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NEO’s TA Score shows that 2 TA indicator(s) are bullish while XGN’s TA Score has 5 bullish TA indicator(s).

  • NEO’s TA Score: 2 bullish, 6 bearish.
  • XGN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, XGN is a better buy in the short-term than NEO.

Price Growth

NEO (@Medical Specialties) experienced а +0.77% price change this week, while XGN (@Medical Specialties) price change was -36.93% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.

Reported Earning Dates

NEO is expected to report earnings on Feb 23, 2027.

XGN is expected to report earnings on Mar 16, 2027.

Industries' Descriptions

@Medical Specialties (-4.92% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
Interact to see
Advertisement

NEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEO has been loosely correlated with ADPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if NEO jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEO
1D Price
Change %
NEO100%
-3.64%
ADPT - NEO
54%
Loosely correlated
-2.97%
NTRA - NEO
52%
Loosely correlated
-2.62%
CSTL - NEO
49%
Loosely correlated
+0.12%
GH - NEO
48%
Loosely correlated
-2.17%
RVTY - NEO
46%
Loosely correlated
-1.01%
More

XGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, XGN has been loosely correlated with NTRA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if XGN jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XGN
1D Price
Change %
XGN100%
-25.92%
NTRA - XGN
38%
Loosely correlated
-2.62%
BDSX - XGN
33%
Poorly correlated
-3.09%
GH - XGN
30%
Poorly correlated
-2.17%
NEO - XGN
28%
Poorly correlated
-3.64%
WGS - XGN
28%
Poorly correlated
-16.57%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FTXG23.360.01
+0.02%
First Trust Nasdaq Food & Beverage ETF (FTXG)
TRIO64.51N/A
N/A
MC Trio Equity Buffered ETF (TRIO)
IBTH22.30-0.01
-0.04%
iShares iBonds Dec 2027 Term Treasury ETF (IBTH)
IQSM39.72-0.08
-0.21%
NYLIM Candriam U.S. Mid Cap Equity ETF (IQSM)
KMCA14.08-0.10
-0.69%
PLUS Korea Manufacturing Core Alliance Index ETF (KMCA)